Skip to main content
. 2017 Sep 11;372(1732):20160277. doi: 10.1098/rstb.2016.0277

Table 2.

HERV-derived T-cell epitopes targeted in cancer.

LTR element immune effectors cancer type study
HERV-K-MEL CD8+ T cells melanoma [98]
HERV-K CD8+ T cells seminoma [99]
HERV-E CD8+ T cells renal cell carcinoma [100]
HERV-H CD8+ T cells colorectal carcinoma [101]